

# Acute Kidney Injury Treatment Market Expected to Reach US\$ 8.2 Bn, Expanding at a CAGR of 7.8% by 2035 | TMR Insight

*The acute kidney injury treatment market is estimated to grow at a CAGR of 7.8% from 2025 to 2035 and reach more than US\$ 8.2 Bn by the end of 2035*

WILMINGTON, DE, UNITED STATES, August 29, 2025 /EINPresswire.com/ --

The global market for [acute kidney injury treatment](#) is a vital and growing sector within the healthcare industry.

Valued at US\$ 3.6 Bn in 2024, this market addresses the critical medical needs of patients suffering from a sudden and severe loss of kidney function. The AKI treatment market is projected for significant growth over the next decade, with a forecast to expand at a Compound Annual Growth Rate (CAGR) of 7.8% from 2025 to 2035. This steady and robust growth is expected to drive the market value to more than US\$ 8.2 Bn by the end of 2035. This expansion is fueled by an increasing

global incidence of AKI, advancements in diagnostic technologies, and the growing adoption of both therapeutic and preventive measures. This report provides a detailed overview of the key factors driving this market, its various treatment segments, and the regional dynamics shaping its trajectory.

For detailed insights and a Sample report, Request access today!

[https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep\\_id=67523](https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=67523)

[mple.php?flag=S&rep\\_id=67523](https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=67523)

Key Market Drivers and Underlying Factors



The robust growth of the AKI treatment market is fundamentally driven by a confluence of demographic, clinical, and technological trends. One of the most significant factors is the increasing global burden of chronic diseases such as diabetes, hypertension, and cardiovascular diseases. These conditions are major risk factors for developing AKI, and as their prevalence rises, so does the demand for effective treatment options. The aging global population is another key driver, as elderly individuals are more susceptible to kidney-related complications due to co-morbidities and a natural decline in kidney function.

Technological advancements have also played a pivotal role. The development of more sophisticated and efficient dialysis machines, particularly in the field of continuous renal replacement therapy (CRRT), has revolutionized the management of critically ill AKI patients. These modern devices offer improved fluid balance control and are more tailored for use in intensive care settings. Furthermore, progress in biomarkers and diagnostic tools has enabled earlier and more accurate detection of AKI, leading to prompt intervention and better patient outcomes. This early diagnosis, in turn, boosts the demand for both therapeutic and supportive care.

The rising number of surgical procedures and hospitalizations globally is a significant contributor to market growth. AKI is a common complication in major surgeries, particularly cardiac and orthopedic procedures. As surgical volumes increase, the incidence of post-operative AKI rises, creating a continuous need for treatment solutions. Additionally, a growing awareness among healthcare professionals and the public about the severity of AKI is leading to more aggressive and preventative management strategies, further driving market expansion.

### Market Segmentation by Treatment, Product, and End-Use

The AKI treatment market is highly segmented, reflecting the diverse range of therapeutic and diagnostic approaches available.

#### By Treatment Type:

**Dialysis:** This segment holds a dominant market share and is divided into several modalities.

**Continuous Renal Replacement Therapy (CRRT):** This is the preferred method for critically ill patients with hemodynamic instability in the intensive care unit (ICU). Its gentle, continuous nature minimizes fluid shifts and electrolyte imbalances.

**Intermittent Hemodialysis (IHD):** A more traditional approach, IHD is typically used for less severe cases or in non-critical settings.

**Peritoneal Dialysis:** Though less common for AKI, it is a viable option, particularly in regions with limited access to hemodialysis.

**Drug Therapy:** While no specific drug can cure AKI, this segment includes medications used for supportive care, such as diuretics to manage fluid overload and vasopressors to maintain blood pressure.

**Others:** This includes supportive care like nutritional management, fluid management, and management of electrolyte imbalances.

**By Product:**

**Dialysis Equipment and Consumables:** This segment includes a wide range of products such as dialysis machines, dialyzers, bloodlines, and catheters, which are essential for renal replacement therapy.

**Diagnostic Tools and Kits:** This includes biomarkers for early detection, such as urine neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and others, which help clinicians identify AKI before significant kidney damage occurs.

**By End-Use:**

**Hospitals:** Hospitals, particularly ICUs and nephrology departments, are the primary end-users of AKI treatment products due to the high volume of patients with complex medical needs.

**Dialysis Centers:** These centers also play a crucial role, especially for patients who transition from hospital care or require long-term treatment if AKI leads to chronic kidney disease.

**Regional Market Dynamics**

The global AKI treatment market exhibits significant regional variation in terms of market size and growth drivers.

**North America:** This region holds the largest market share, driven by a well-established healthcare infrastructure, high healthcare expenditure, and the presence of leading market players. The U.S. and Canada have high rates of chronic diseases and an aging population, which contribute to a high incidence of AKI. Favorable reimbursement policies and advanced diagnostic capabilities further bolster market growth.

**Europe:** Europe is another mature market, characterized by a strong focus on research and development, particularly in innovative therapeutic approaches. Countries like Germany, the UK, and France are key contributors due to high healthcare standards and government initiatives aimed at improving patient outcomes.

**Asia-Pacific:** This region is poised to be the fastest-growing market for AKI treatment. The growth is fueled by a massive population base, increasing healthcare spending, and a rising prevalence

of diabetes and hypertension. Rapidly developing economies like China and India are seeing a surge in hospital infrastructure development and an increase in public awareness about kidney health. Furthermore, a growing trend of medical tourism for complex procedures also contributes to the market's expansion in this region.

Latin America & Middle East & Africa: These regions are emerging markets with considerable growth potential. Improving economic conditions, increasing healthcare access, and a rising awareness of kidney diseases are driving market growth. However, challenges such as limited access to advanced technologies and lack of specialized healthcare professionals in some areas may hinder rapid expansion.

### Competitive Landscape and Future Outlook

The global AKI treatment market is highly competitive, with a few key players dominating the space. Major companies include Baxter International Inc., Fresenius Medical Care AG & Co. KGaA, Nikkiso Co., Ltd., and B. Braun Melsungen AG. These companies are focused on strategic initiatives such as product innovation, research and development, and global partnerships to maintain their competitive edge. The market is also seeing the emergence of smaller players specializing in novel diagnostic biomarkers and point-of-care devices.

AM-Pharma

Aptabio Therapeutics

Arch Biopartners

Novartis AG

Guard Therapeutics

Renibus Therapeutics

Mission Therapeutics

Unicycive Therapeutics Inc.

Baxter International Inc.

ICU Medical

B. Braun Melsungen AG

Fresenius Kabi

Amanta Healthcare

Pfizer, Inc.

Sanofi S.A.

The future of the AKI treatment market looks promising, with several key trends on the horizon. The focus is shifting towards early diagnosis and preventative care to mitigate the severity of AKI. The development of novel biomarkers and point-of-care diagnostic devices will be crucial. There is also a strong push towards personalized medicine, where treatments are tailored to the individual patient's needs, potentially leading to more effective outcomes. The integration of advanced technologies like artificial intelligence (AI) for risk prediction and treatment optimization is also expected to shape the market's future trajectory. Overall, the market is set

for sustained growth, driven by a persistent need for effective and accessible treatments for this life-threatening condition.

Access More Trending Exclusive Reports by Transparency Market Research:

Kidney Cancer Drugs Market: <https://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html>

Kidney Fibrosis Treatment Market: <https://www.transparencymarketresearch.com/kidney-fibrosis-treatment.html>

Kidney Dialysis Equipment Market: <https://www.transparencymarketresearch.com/kidney-dialysis-equipment-market.html>

Kidney Stone Retrieval Devices Market: <https://www.transparencymarketresearch.com/kidney-stone-retrieval-devices-market.html>

T-cell Acute Lymphoblastic Leukemia Market: <https://www.transparencymarketresearch.com/t-cell-acute-lymphoblastic-leukemia-market.html>

Severe Acute Respiratory Syndrome Treatment Market:  
<https://www.transparencymarketresearch.com/severe-acute-respiratory-syndrome-treatment-market.html>

Chronic Kidney Disease (CKD) Drugs Market:  
<https://www.transparencymarketresearch.com/chronic-kidney-disease.html>

Chronic Kidney Disease [CKD] Nutritional Supplement Market:  
<https://www.transparencymarketresearch.com/chronic-kidney-disease-ckd-nutritional-supplement-market.html>

Ketoanalogue for Kidney Disease Market:  
<https://www.transparencymarketresearch.com/ketoanalogue-for-kidney-disease-market.html>

Rare Kidney Diseases Treatment Market: <https://www.transparencymarketresearch.com/rare-kidney-diseases-treatment-market.html>

Chronic Kidney Disease Treatment Market:  
<https://www.transparencymarketresearch.com/chronic-kidney-disease-treatment-market.html>

Reperfusion Injury Market: <https://www.transparencymarketresearch.com/reperfusion-injury-market.html>

Vascular Injury Treatment Market: <https://www.transparencymarketresearch.com/vascular-injury-treatment-market.html>

Acute Myeloid Leukemia (AML) Therapeutic Market:  
<https://www.transparencymarketresearch.com/acute-myeloid-leukemia-therapeutics-market.html>

Acute Ischemic Stroke Diagnosis and Treatment Market:  
<https://www.transparencymarketresearch.com/acute-ischemic-stroke-treatment.html>

## About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: <https://www.transparencymarketresearch.com>

Email: [sales@transparencymarketresearch.com](mailto:sales@transparencymarketresearch.com)

Atil Chaudhari

Transparency Market Research Inc.

+ +1 518-618-1030

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/844250897>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.